Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma - PubMed (original) (raw)

Review

Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma

Xiong-Zhi Wu et al. J Gastroenterol Hepatol. 2007 Aug.

Abstract

Hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of hepatocellular carcinoma (HCC); suppresses differentiation and apoptosis of HCC; and consequently leads to resistance of transarterial embolization (with or without chemotherapy). Because transarterial embolization contributes to angiogenesis via inducing hypoxia, therapy combined with transarterial embolization and antiangiogenic therapy provides a new strategy for the treatment of HCC. Unfortunately, hypoxia leads to the escape of HCC cells from transarterial embolization and antiangiogenic therapy. Thus combined therapy that induces and targets hypoxia may be of benefit to HCC patients. Because angiogenesis plays an important role in recurrence of HCC after resection, antiangiogenic therapy is beneficial to HCC patients following surgical resection of the tumor.

PubMed Disclaimer

Comment in

Growth factors as indicators of prognosis in liver failure.
Shackel NA. Shackel NA. J Gastroenterol Hepatol. 2007 Aug;22(8):1171-3. doi: 10.1111/j.1440-1746.2007.05005.x. J Gastroenterol Hepatol. 2007. PMID: 17688658 No abstract available.

Cited by

Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma.
Hu F, Deng X, Yang X, Jin H, Gu D, Lv X, Wang C, Zhang Y, Huo X, Shen Q, Luo Q, Zhao F, Ge T, Zhao F, Chu W, Shu H, Yao M, Fan J, Qin W. Hu F, et al. Oncogene. 2015 Dec 3;34(49):6007-17. doi: 10.1038/onc.2015.49. Epub 2015 Mar 9. Oncogene. 2015. PMID: 25745995
Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells.
Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL, González-Gallego J. Carbajo-Pescador S, et al. Br J Cancer. 2013 Jul 9;109(1):83-91. doi: 10.1038/bjc.2013.285. Epub 2013 Jun 11. Br J Cancer. 2013. PMID: 23756865 Free PMC article.
Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M, Fan B, Cao G, Zong R, Feng L, Sun H. Ren M, et al. BMC Genomics. 2023 Dec 14;24(1):776. doi: 10.1186/s12864-023-09876-3. BMC Genomics. 2023. PMID: 38097948 Free PMC article.
Emerging theragnostic radionuclide applications for hepatocellular carcinoma.
Nyakale NE, Aldous C, Gutta AA, Khuzwayo X, Harry L, Sathekge MM. Nyakale NE, et al. Front Nucl Med. 2023 Oct 25;3:1210982. doi: 10.3389/fnume.2023.1210982. eCollection 2023. Front Nucl Med. 2023. PMID: 39355044 Free PMC article. Review.
SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer.
Zubiete-Franco I, García-Rodríguez JL, Lopitz-Otsoa F, Serrano-Macia M, Simon J, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gutiérrez-de-Juan V, López de Davalillo S, Carlevaris O, Beguiristain Gómez A, Villa E, Calvisi D, Martín C, Berra E, Aspichueta P, Beraza N, Varela-Rey M, Ávila M, Rodríguez MS, Mato JM, Díaz-Moreno I, Díaz-Quintana A, Delgado TC, Martínez-Chantar ML. Zubiete-Franco I, et al. EBioMedicine. 2019 Feb;40:406-421. doi: 10.1016/j.ebiom.2018.12.031. Epub 2018 Dec 26. EBioMedicine. 2019. PMID: 30594553 Free PMC article.

Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma - PubMed (original) (raw)